(Q53984573)

English

A six-week dose-response study of the ocular hypotensive effect of dorzolamide with a one-year extension. Dorzolamide Dose-Response Study Group.

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 May 2018

http://europepmc.org/abstract/MED/8694086

A six-week dose-response study of the ocular hypotensive effect of dorzolamide with a one-year extension. Dorzolamide Dose-Response Study Group. (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 May 2018

http://europepmc.org/abstract/MED/8694086

author name string

E Strahlman

1

1 reference

Europe PubMed Central

PubMed publication ID

23 May 2018

http://europepmc.org/abstract/MED/8694086

R Tipping

2

1 reference

Europe PubMed Central

PubMed publication ID

23 May 2018

http://europepmc.org/abstract/MED/8694086

R Vogel

3

1 reference

Europe PubMed Central

PubMed publication ID

23 May 2018

http://europepmc.org/abstract/MED/8694086

language of work or name

0 references

publication date

1 August 1996

1 reference

Europe PubMed Central

PubMed publication ID

23 May 2018

http://europepmc.org/abstract/MED/8694086

American Journal of Ophthalmology

1 reference

Europe PubMed Central

PubMed publication ID

23 May 2018

http://europepmc.org/abstract/MED/8694086

122

1 reference

Europe PubMed Central

PubMed publication ID

23 May 2018

http://europepmc.org/abstract/MED/8694086

2

1 reference

Europe PubMed Central

PubMed publication ID

23 May 2018

http://europepmc.org/abstract/MED/8694086

183-194

1 reference

Europe PubMed Central

PubMed publication ID

23 May 2018

http://europepmc.org/abstract/MED/8694086

MK-507 (L-671,152), a topically active carbonic anhydrase inhibitor, reduces aqueous humor production in monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972009-4

7 January 2021

Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972009-4

7 January 2021

MK-507 versus sezolamide. Comparative efficacy of two topically active carbonic anhydrase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972009-4

7 January 2021

Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972009-4

7 January 2021

A DISTRIBUTION-FREE k-SAMPLE TEST AGAINST ORDERED ALTERNATIVES

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972009-4

7 January 2021

Asymptotically Efficient Rank Invariant Test Procedures

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972009-4

7 January 2021

Long-term evaluation of 0.25% levobunolol and timolol for therapy for elevated intraocular pressure.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972009-4

7 January 2021

Minimum concentration of levobunolol required to control intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972009-4

7 January 2021

Topical timolol administration reduces the incidence of glaucomatous damage in ocular hypertensive individuals. A randomized, double-masked, long-term clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972009-4

7 January 2021

Absence of metabolic effects of the topical carbonic anhydrase inhibitors MK-927 and sezolamide during two-week ocular administration to normal subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972009-4

7 January 2021

A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. International Dorzolamide Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972009-4

7 January 2021

Identifiers

10.1016/S0002-9394(14)72009-4

1 reference

Europe PubMed Central

PubMed publication ID

23 May 2018

http://europepmc.org/abstract/MED/8694086

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 May 2018

http://europepmc.org/abstract/MED/8694086

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53984573&oldid=1371489303"